.jpeg)
2026-08-07 07:30:56
Mavacamten is the first cardiac myosin inhibitor targeting the underlying pathophysiology of obstructive hypertrophic cardiomyopathy (oHCM). This article reviews its treatment duration, clinical efficacy, head-to-head comparisons with conventional therapies, and long-term management strategies.
2026-08-07 07:13:02
Belzutifan is the first approved hypoxia-inducible factor-2α (HIF-2α) inhibitor, indicated for VHL disease-associated tumors, advanced renal cell carcinoma, and pheochromocytoma/paraganglioma. This article provides a systematic overview of its approved indications, adult and pediatric weight-based dosing, administration guidelines, drug interactions, and safety monitoring requirements to support standardized clinical use.
2026-08-07 06:55:55
Encorafenib is an oral selective BRAF V600 kinase inhibitor used in combination with binimetinib or cetuximab for BRAF-mutant melanoma, metastatic colorectal cancer, and non-small cell lung cancer. This article provides a systematic review of its label highlights, tumor-specific dosing schedules, administration timing, drug interactions, and special population guidance to support standardized clinical use.
2026-08-06 07:53:13
Alpelisib (Piqray) and inavolisib (Itovebi) both target the PI3Kα pathway in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, yet their approved indications, combination partners, and evidence bases differ. This article compares the two agents across treatment line, clinical evidence, and safety considerations.
2026-08-06 07:40:26
Selumetinib (Koselugo) is the first approved MEK1/2 inhibitor for symptomatic, inoperable plexiform neurofibromas associated with Neurofibromatosis Type 1 (NF1), offering a precision-targeted therapy that reduces tumor volume and alleviates disease-related symptoms in children and adults.
2026-08-06 07:11:28
Phase 3 FIGHT-302 data presented at the 2026 ASCO Annual Meeting demonstrate that pemigatinib (Pemazyre) as first-line monotherapy significantly prolongs progression-free survival versus gemcitabine plus cisplatin in patients with FGFR2-rearranged unresectable cholangiocarcinoma, establishing a new precision-targeted standard for this molecularly defined population.
2026-08-06 06:54:38
Selpercatinib (Retevmo) is the first approved highly selective RET kinase inhibitor, dosed twice daily at 120 mg or 160 mg based on body weight, indicated for RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer, and other RET-altered malignancies.
2026-08-06 06:49:15
Mitotane is the cornerstone drug for adrenocortical carcinoma treatment, yet its side-effect profile extends well beyond common gastrointestinal discomfort to include adrenal insufficiency, neurological effects, and hepatic changes, necessitating systematic monitoring and proactive clinical management.
2026-08-05 03:49:14
Axitinib is a highly selective oral VEGFR tyrosine kinase inhibitor approved for advanced renal cell carcinoma (RCC) as first-line combination therapy and second-line monotherapy. This article reviews its indications, composition, mechanism of action, critical pre-treatment warnings, and drug interactions to support safe clinical use.
2026-08-05 03:34:24
Capmatinib (Tabrecta) is the first highly selective MET inhibitor approved for MET exon 14 skipping mutation-positive non-small cell lung cancer (NSCLC). This article covers the purchasing channels, reliability assessment, efficacy data, version differences, and safety monitoring tips for the Laos generic version, helping patients make informed treatment decisions.
2026-08-04 03:43:45
Eltrombopag olamine is a key oral thrombopoietin receptor agonist (TPO-RA) used in the treatment of immune thrombocytopenia (ITP) and severe aplastic anemia (SAA). This guide details the correct administration timing requirements, alternative options when the originator product is unavailable, switching precautions, and safety monitoring to support standardized patient care.
2026-08-04 03:22:38
Osimertinib is a cornerstone targeted therapy for EGFR mutation-positive non-small cell lung cancer (NSCLC). This comprehensive guide covers its composition, mechanism of action, critical food interactions (three fruits and vegetables to avoid), pre-treatment assessments, and drug interaction management to ensure safe and effective use.
